Fennec (FENC) Former Director Rosty Receives 2,778-Share Award

What Happened

• Raykov Rosty, identified as a former director of Fennec Pharmaceuticals (FENC), acquired 2,778 shares on July 31, 2026. The shares were reported as an award/acquisition (code A) at $0.00 per share — a release of restricted shares rather than a market purchase.

Key Details

• Transaction date: 2026-07-31 (acquisition code A)
• Price: $0.00 per share; total reported value $0
• Number of shares acquired: 2,778
• Footnote: These shares were released from restriction from an award originally granted on 2024-05-16
• Filing: Form 4 filed 2026-08-03 (timely within the required reporting window)
• Shares owned after transaction: not specified in the provided filing excerpt

Context

• This was a vesting/release of previously awarded restricted stock (typical for equity compensation) and not an open‑market purchase or sale. Such releases reflect fulfillment of award conditions and are neutral factual events for retail investors — they do not by themselves signal a buy or sell intent.